Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia.

ABSTRACT:

Background

The aryl hydrocarbon receptor (AHR) is expressed in the intestine and liver, where it has pleiotropic functions and target genes. This study aims to explore the potential implication of AHR in cancer cachexia, an inflammatory and metabolic syndrome contributing to cancer death. Specifically, we tested the hypothesis that targeting AHR can alleviate cachectic features, particularly through the gut-liver axis.

Methods

AHR pathways were explored in multiple tissues from four experimental mouse models of cancer cachexia (C26, BaF3, MC38 and APC^Min/+ ) and from non-cachectic mice (sham-injected mice and non-cachexia-inducing [NC26] tumour-bearing mice), as well as in liver biopsies from cancer patients. Cachectic mice were treated with an AHR agonist (6-form

SUBMITTER: Dolly A 

PROVIDER: S-EPMC10235873 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature